The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care medicine and symptomatic treatments. Its immunopathogenesis is fundamentally a T-cell-dependent autoimmune process resulting from loss of tolerance toward self-antigens in the thymus. Thymectomy is based on this immunological background. For MG patients who are inadequately controlled with sufficient symptomatic treatment or fail to achieve remission after thymectomy, remission is usually achieved through the addition of other immunotherapies. These immunotherapies can be classified into two groups: rapid induction and long-term maintenance. Rapid induction therapy includes intravenous immunoglobulin (IVIg) and plasma exchange (PE). These prod...
Myasthenia gravis is a disease affecting the neuromuscular junction. Still today it is not very clea...
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder characterized by fluctuating muscle ...
This month, we discuss three papers which publish the results of trials into potential treatment app...
The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care m...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the era of mole...
Myasthenia gravis (MG) with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is oft...
Myasthenia Gravis (MG) is an autoimmune disease affecting neuromuscular transmission, in which the t...
The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half...
Renato Mantegazza, Silvia Bonanno, Giorgia Camera, Carlo AntozziDepartment of Neuromuscular Diseases...
In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the...
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndrome...
Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against acety...
Myasthenia gravis (MG) is a chronic autoimmune disease with fluctuating muscle weakness and fatigabi...
Earlier diagnosis and the availability of effective treatments have reduced the burden of high morta...
Myasthenia gravis is a disease affecting the neuromuscular junction. Still today it is not very clea...
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder characterized by fluctuating muscle ...
This month, we discuss three papers which publish the results of trials into potential treatment app...
The prognosis of myasthenia gravis (MG) has improved dramatically due to advances in critical-care m...
Immunosuppression is the mainstay of treatment for myasthenia gravis (MG). In this paper, we review ...
Substantial therapeutic progress has been made in myasthenia gravis (MG) even before the era of mole...
Myasthenia gravis (MG) with antibodies against the muscle-specific tyrosine kinase (MuSK abs) is oft...
Myasthenia Gravis (MG) is an autoimmune disease affecting neuromuscular transmission, in which the t...
The prognosis for patients with myasthenia gravis (MG) has improved significantly over the past half...
Renato Mantegazza, Silvia Bonanno, Giorgia Camera, Carlo AntozziDepartment of Neuromuscular Diseases...
In recent years, the discovery of new autoantigens and the use of sensitive assays have expanded the...
Myasthenia gravis (MG), Lambert-Eaton myasthenic syndrome (LEMS), and congenital myasthenic syndrome...
Myasthenia gravis (MG) is an autoimmune disease caused by complement-fixing antibodies against acety...
Myasthenia gravis (MG) is a chronic autoimmune disease with fluctuating muscle weakness and fatigabi...
Earlier diagnosis and the availability of effective treatments have reduced the burden of high morta...
Myasthenia gravis is a disease affecting the neuromuscular junction. Still today it is not very clea...
Myasthenia gravis (MG) is an autoimmune, neuromuscular disorder characterized by fluctuating muscle ...
This month, we discuss three papers which publish the results of trials into potential treatment app...